Precision Oncology Ireland
Project Title: Co-Development of a Patient Involvement Plan for Precision Oncology Ireland
Precision Oncology Ireland (POI) is a consortium of five Irish universities, six Irish cancer research charities, and ten international companies, aiming to develop new diagnostics and therapeutics for personalised cancer treatment. The consortium is part-funded by Science Foundation Ireland under their Strategic Partnership Programme and launched in November 2019. The combined SFI, charity, and industrial funding commitment will total €11.9 million over the next five years.
Precision (or 'personalised') medicine uses data about a person’s genes (genomics), along with additional information on their cancer so they can target treatment accordingly. POI will use cutting-edge technologies to generate unique genetic and molecular profiles for each patient’s cancer. The results will be better diagnostics, personalised cancer treatment, and faster drug discovery and development.
This is the first time that researchers, charities, and industry have combined forces to tackle this challenge. These partners come together with a joint view of achieving a greater impact for patients by uniting their investments in the POI programme.
Benefit to Cancer Patients
We want to involve cancer patients in POI from the beginning, bringing a collaborative dynamic to the research process and making our work more relevant and responsive to patients' needs.
Our goals are to develop a relationship with those suffering from cancer and their families to make the patient's voice heard in our research.